Cardiovascular Drugs Practice Questions

Q: Which of the following drugs is not a blocker of L-type calcium channels?

Ethosuximide. The core concept tested here is the classification of calcium channel blockers (CCBs) based on their specific channel targets and clinical applications. **1. Why Ethosuximide is the correct answer:** Ethosuximide is a primary anti-epileptic drug used for **Absence seizures (Petit mal)**. Its mechanism of action involves the selective blockade of **T-type (Transient) calcium calcium channels** in thalamic neurons. It does not inhibit L-type (Long-lasting) channels, which are predominantly found in vascular smooth muscle and cardiac tissue. **2. Why the other options are incorrect:** Options A, B, and D are all classic **L-type Calcium Channel Blockers**, categorized into two chemical classes [1]: * **Amlodipine (Option B):** A Dihydropyridine (DHP) [2]. It selectively blocks L-type channels in vascular smooth muscle, causing vasodilation [3]. It is used for hypertension and angina. * **Verapamil (Option D) & Diltiazem (Option A):** Non-Dihydropyridines. They block L-type channels in both the myocardium and specialized conduction tissue (SA/AV nodes) [1], [3]. They are used for arrhythmias (Rate control), angina, and hypertension. **3. NEET-PG High-Yield Pearls:** * **L-type channels:** "L" stands for **L**ong-lasting/Large current. Target for CVS drugs (HTN, Angina, Arrhythmia) [1]. * **T-type channels:** "T" stands for **T**ransient/Tiny current. Target for Ethosuximide and Valproate (in the thalamus) and Mibefradil (cardiac). * **N-type channels:** "N" stands for **N**euronal. Blocked by **Ziconotide** (used for chronic pain). * **Drug of Choice (DOC):** Ethosuximide is the DOC for Absence seizures in children; however, if generalized tonic-clonic seizures (GTCS) coexist, Valproate is preferred.

Q: A 75-year-old, obese female is admitted with acute myocardial infarction and congestive heart failure, then has an episode of ventricular tachycardia. She is prescribed multiple medications and soon develops confusion and slurred speech. What is the most likely cause of this confusion?

Lidocaine. **Explanation:** The correct answer is **Lidocaine**. Lidocaine is a Class IB antiarrhythmic used for ventricular arrhythmias, especially in the setting of acute myocardial infarction (MI). Unlike other antiarrhythmics, Lidocaine toxicity primarily manifests as **Central Nervous System (CNS) side effects**. Early signs include confusion, slurred speech, tremors, and paresthesia, which can progress to seizures and coma. In this patient, two factors increase the risk of toxicity: 1. **Congestive Heart Failure (CHF):** Lidocaine is metabolized by the liver. In CHF, reduced hepatic blood flow leads to decreased clearance and toxic accumulation of the drug. 2. **Age:** Elderly patients often have reduced metabolic capacity. **Why the other options are incorrect:** * **Captopril (ACE Inhibitor):** Common side effects include dry cough, hyperkalemia, and angioedema. It does not typically cause acute confusion or slurred speech. * **Digoxin:** Toxicity usually presents with gastrointestinal symptoms (nausea/vomiting), visual disturbances (xanthopsia/yellow-green halos), and cardiac arrhythmias (e.g., PVCs, AV block). * **Furosemide:** A loop diuretic that causes electrolyte imbalances (hypokalemia, hyponatremia) and dehydration. While severe hyponatremia can cause confusion, it is less likely to present acutely with slurred speech immediately following VT treatment. **NEET-PG High-Yield Pearls:** * **Lidocaine Metabolism:** It has a high first-pass metabolism; hence, it is given only IV. * **Drug of Choice:** While Lidocaine was historically the first choice for post-MI VT, **Amiodarone** is now preferred due to a better safety profile. * **CNS Toxicity Sequence:** "SAMS" (Slurred speech, Altered mental status, Muscle twitching, Seizures).

Q: A hypertensive patient with BP 160/90 mm Hg presents with an increased level of Lipoprotein A. Which hypolipidemic drug will you prescribe?

Niacin. The correct answer is **Niacin (Nicotinic Acid)**. **1. Why Niacin is Correct:** Lipoprotein(a) [Lp(a)] is an independent genetic risk factor for atherosclerosis and cardiovascular disease. Most conventional lipid-lowering drugs (like statins and fibrates) have little to no effect on Lp(a) levels. **Niacin** is the most potent traditional hypolipidemic agent for reducing Lp(a) levels (by approximately 20-30%) [1]. It works by inhibiting the synthesis of apolipoprotein B-100 and reducing the assembly of VLDL, which subsequently lowers LDL and Lp(a). **2. Why Other Options are Incorrect:** * **Pitavastatin:** While statins are the first-line treatment for lowering LDL-C, they do not significantly reduce Lp(a) [1]. In some cases, statins may even cause a paradoxical slight increase in Lp(a) levels. * **Fenofibrate:** Fibrates primarily target triglycerides by activating PPAR-α. They have a negligible effect on Lp(a) concentrations [1]. * **Ezetimibe:** This drug inhibits cholesterol absorption in the small intestine. While it lowers LDL-C, it has no clinically significant effect on Lp(a) [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most effective drug to increase HDL:** Niacin [1]. * **Most effective drug to lower Triglycerides:** Fibrates [1]. * **Most effective drug to lower LDL:** Statins (specifically Rosuvastatin/Atorvastatin) [1]. * **Niacin Side Effects:** Cutaneous flushing (mediated by Prostaglandin $D_2$; prevented by Aspirin), Hyperuricemia (can precipitate Gout), and Hyperglycemia (caution in Diabetics). * **Newer Agents for Lp(a):** PCSK9 inhibitors (Evolocumab) also reduce Lp(a), but Niacin remains the classic answer for this specific pharmacological property in exams.

Q: Which of the following drugs commonly causes constipation?

Verapamil. **Explanation:** **Verapamil** is a non-dihydropyridine Calcium Channel Blocker (CCB) that is notorious for causing **constipation** (seen in up to 25% of patients). The underlying mechanism involves the blockade of L-type calcium channels in the smooth muscles of the gastrointestinal tract. Calcium entry is essential for the contraction of colonic smooth muscle; by inhibiting this, Verapamil reduces intestinal motility and increases transit time, leading to constipation. **Analysis of Incorrect Options:** * **Propranolol (Beta-blocker):** More commonly associated with fatigue, bradycardia, and bronchospasm. While it can occasionally cause GI upset, it is not a classic cause of constipation. * **Nitroglycerin (Nitrate):** Its primary side effects are related to vasodilation, such as throbbing headaches, flushing, and orthostatic hypotension. * **Captopril (ACE Inhibitor):** Most famous for causing a dry cough (due to bradykinin accumulation), angioedema, and hyperkalemia. **High-Yield Clinical Pearls for NEET-PG:** * **Verapamil** is the CCB with the most significant negative inotropic effect; it is contraindicated in Heart Failure. * Among CCBs, constipation is most severe with Verapamil and least common with dihydropyridines like Amlodipine. * **Drug of Choice:** Verapamil is a drug of choice for Supraventricular Tachycardia (SVT) and prophylaxis of Cluster Headaches. * **Gingival Hyperplasia:** Along with Phenytoin and Cyclosporine, CCBs (especially Nifedipine and Verapamil) are common causes of gum enlargement.

Q: Which of the following beta-blockers can be used in renal failure, EXCEPT?

Sotalol. ### Explanation The key to answering this question lies in understanding the **pharmacokinetics** of beta-blockers, specifically their route of elimination. **1. Why Sotalol is the Correct Answer:** Beta-blockers are broadly categorized based on their lipid solubility. **Sotalol** is a highly water-soluble (hydrophilic) beta-blocker. Unlike lipid-soluble drugs that are metabolized by the liver, hydrophilic drugs are primarily excreted **unchanged by the kidneys**. In patients with renal failure, the clearance of Sotalol is significantly reduced, leading to toxic accumulation and an increased risk of life-threatening arrhythmias (like Torsades de Pointes due to its Class III antiarrhythmic properties). Therefore, it must be avoided or strictly dose-adjusted in renal impairment. **2. Analysis of Incorrect Options:** * **Propranolol:** This is the prototype of highly lipid-soluble beta-blockers. it undergoes extensive hepatic metabolism. Since it does not rely on renal excretion, it is safe to use in renal failure. * **Pindolol and Oxprenolol:** These are moderately lipid-soluble drugs. They undergo significant hepatic metabolism and are generally considered safe for use in patients with decreased renal function without major dose adjustments. **3. NEET-PG High-Yield Pearls:** * **Lipid Soluble (Hepatic Clearance):** Propranolol, Metoprolol, Labetalol, Carvedilol. (Mnemonic: **L**ipid = **L**iver). Safe in renal failure. * **Water Soluble (Renal Clearance):** Atenolol, Sotalol, Nadolol. (Mnemonic: **S**afe **A**nswer **N**eeded for Kidney). Avoid/Adjust in renal failure. * **Esmolol:** Unique because it is metabolized by **RBC esterases**, giving it the shortest half-life (~9 minutes). * **Bisoprolol:** Undergoes balanced clearance (50% hepatic, 50% renal).

Q: High-density lipoprotein (HDL) levels are specifically increased by which of the following medications?

Niacin. **Explanation:** **Niacin (Vitamin B3)** is the correct answer because it is the most potent agent currently available for increasing **HDL-C levels** (typically by 15–35%). It achieves this primarily by inhibiting the surface expression of ATP synthase beta, which decreases the hepatic uptake and catabolism of HDL particles, thereby increasing their half-life in the circulation. Additionally, Niacin inhibits adipose tissue lipolysis, reducing the delivery of free fatty acids to the liver and subsequently lowering VLDL and LDL production. **Analysis of Incorrect Options:** * **Lovastatin (Statins):** Their primary mechanism is inhibiting HMG-CoA reductase. While they are the first-line drugs for lowering **LDL-C**, their effect on increasing HDL is modest (5–10%). * **Gemfibrozil (Fibrates):** These are PPAR-α agonists primarily used to lower **Triglycerides**. While they do increase HDL, their effect is generally less consistent and less potent than Niacin. * **Probucol:** This is an older lipid-lowering agent that is unique because it actually **decreases HDL levels** (by inhibiting CETP-like activity), making it the opposite of what the question asks. **NEET-PG High-Yield Pearls:** * **Side Effects of Niacin:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin D2/E2), which can be prevented by pre-treatment with **Aspirin**. It can also cause hyperuricemia (gout) and hyperglycemia (diabetes). * **Drug of Choice:** Statins are the DOC for hypercholesterolemia; Fibrates are the DOC for hypertriglyceridemia. * **Combination Therapy:** Combining Niacin with Statins increases the risk of **myopathy**, though less so than the Statin-Gemfibrozil combination.

Q: Which of the following is a selective myosin activator?

Omecamtiv Mecarbil. **Explanation:** **Omecamtiv Mecarbil** is a novel **selective cardiac myosin activator** (cardiac inotrope) [1]. Unlike traditional inotropes, it does not increase intracellular calcium or cAMP. Instead, it binds directly to the catalytic domain of cardiac myosin, accelerating the rate-limiting step of the cross-bridge cycle (transition from the weak-binding to the strong-binding state). This increases the number of myosin heads bound to actin during systole, thereby increasing the **force of contraction** and **systolic ejection period** without increasing myocardial oxygen consumption or heart rate. **Analysis of Incorrect Options:** * **A. Istaroxime:** This is a dual-action investigational drug that inhibits Na+/K+ ATPase (like Digoxin) and activates the SERCA2a pump. It increases calcium sequestration but is not a direct myosin activator. * **C. Tolvaptan:** This is a selective **Vasopressin V2 receptor antagonist** (Aquaretic) used in the management of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD) [1]. * **D. Levosimendan:** This is a **Calcium Sensitizer** [1]. It binds to Troponin C, increasing the sensitivity of the contractile apparatus to existing calcium. It also acts as a K+ channel opener, causing vasodilation (Inodilator). **High-Yield Clinical Pearls for NEET-PG:** * **Omecamtiv Mecarbil** is specifically used in Heart Failure with Reduced Ejection Fraction (HFrEF) [1]. * **Key Advantage:** It improves cardiac function without the pro-arrhythmic risks associated with drugs that increase intracellular calcium (like Dobutamine or Milrinone). * **Mechanism Mnemonic:** "Omecamtiv **M**ecarbil **M**oves **M**yosin."

Q: A patient presents to the medicine emergency with severe CHF. A drug is chosen which is a short-term ionotropic agent with selective adrenergic agonistic activity but lacking dopaminergic agonistic activity. What can this drug be?

Dobutamine. **Explanation:** The patient is presenting with severe Congestive Heart Failure (CHF), requiring an inotropic agent to improve cardiac output. **Why Dobutamine is correct:** Dobutamine is a synthetic catecholamine that acts as a **selective $\beta_1$-adrenergic agonist**. It increases myocardial contractility (positive inotropy) with a relatively lesser effect on heart rate (chronotropy). Crucially, unlike dopamine, it has **no action on dopaminergic ($D_1, D_2$) receptors**. It is the drug of choice for short-term management of cardiac decompensation post-surgery or in CHF/cardiogenic shock. **Why other options are incorrect:** * **Dopamine:** While it is an inotrope, it acts on **dopaminergic receptors** (causing renal vasodilation at low doses) as well as $\beta_1$ and $\alpha_1$ receptors. The question specifically excludes dopaminergic activity. * **Amrinone (Inamrinone):** This is a **Phosphodiesterase-3 (PDE3) inhibitor**, not an adrenergic agonist. It increases cAMP levels to exert inotropic effects but works via a different mechanism than the one described. * **Salmeterol:** This is a long-acting **$\beta_2$-selective agonist** used primarily as a bronchodilator in asthma/COPD; it is not used as an inotropic agent in acute CHF. **High-Yield Clinical Pearls for NEET-PG:** * **Dobutamine** is often preferred over Dopamine in cardiogenic shock because it reduces afterload (slight $\beta_2$ effect) and has a lower tendency to cause tachycardia. * **Isoprenaline** is a non-selective $\beta$-agonist ($\beta_1 = \beta_2$), whereas Dobutamine is $\beta_1$ selective. * **Tolerance:** Tachyphylaxis (decreased response) can occur with Dobutamine if used continuously for more than 72 hours due to receptor down-regulation.

Question 1

Which of the following drugs is not a blocker of L-type calcium channels?

Accepted Answer

Ethosuximide

Answer

Diltiazem

Answer

Amlodipine

Answer

Verapamil

Question 2

A 75-year-old, obese female is admitted with acute myocardial infarction and congestive heart failure, then has an episode of ventricular tachycardia. She is prescribed multiple medications and soon develops confusion and slurred speech. What is the most likely cause of this confusion?

Accepted Answer

Lidocaine

Answer

Captopril

Answer

Digoxin

Answer

Furosemide

Question 3

A hypertensive patient with BP 160/90 mm Hg presents with an increased level of Lipoprotein A. Which hypolipidemic drug will you prescribe?

Accepted Answer

Niacin

Answer

Fenofibrate

Answer

Pitavastatin

Answer

Ezetimibe

Question 4

Which of the following drugs commonly causes constipation?

Accepted Answer

Verapamil

Answer

Propranolol

Answer

Nitroglycerin

Answer

Captopril

Question 5

Which of the following beta-blockers can be used in renal failure, EXCEPT?

Accepted Answer

Sotalol

Answer

Propranolol

Answer

Pindolol

Answer

Oxprenolol

Question 6

High-density lipoprotein (HDL) levels are specifically increased by which of the following medications?

Accepted Answer

Niacin

Answer

Lovastatin

Answer

Gemfibrozil

Answer

Probucol

Question 7

Which drug is most likely to cause maximum tachycardia?

Accepted Answer

Nifedipine

Answer

Verapamil

Answer

Propranolol

Answer

Amlodipine

Question 8

Which of the following is a selective myosin activator?

Accepted Answer

Omecamtiv Mecarbil

Answer

Istaroxime

Answer

Tolvaptan

Answer

Levosimendan

Question 9

Nicotinic acid acts by which of the following mechanisms?

Accepted Answer

Inhibiting the release of free fatty acids from adipose tissue

Answer

Inhibiting HMG-CoA synthatase

Answer

Inhibiting HMG CoA reductase

Answer

Decreasing absorption of cholesterol

Question 10

A patient presents to the medicine emergency with severe CHF. A drug is chosen which is a short-term ionotropic agent with selective adrenergic agonistic activity but lacking dopaminergic agonistic activity. What can this drug be?

Accepted Answer

Dobutamine

Answer

Dopamine

Answer

Amrinone

Answer

Salmeterol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?